Beta Bionics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	110.24	100.25	65.12	12	0.18
Revenue Growth (YoY)	57.87%	53.94%	442.93%	6601.12%	-
Cost of Revenue	47.24	44.71	29.24	5.69	-
Gross Profit	63	55.54	35.89	6.31	0.18
Selling, General & Admin	102.76	92.43	54.96	24.22	34.6
Research & Development	37.56	34.79	26.18	17.94	31.43
Total Operating Expenses	140.31	127.22	81.14	42.16	66.02
Operating Income	-77.31	-71.68	-45.25	-35.85	-65.84
Interest Income	10.87	10.93	3.91	1.78	0.2
Interest Expense	-	-	-	-	-0.01
Other Non-Operating Income (Expense)	2.38	-12.45	-13.41	-10.03	0.91
Total Non-Operating Income (Expense)	13.25	-1.52	-9.51	-8.25	1.09
Pretax Income	-64.06	-73.2	-54.76	-44.1	-64.75
Net Income	-66.44	-73.2	-54.76	-44.1	-64.75
Net Income to Common	-66.44	-73.2	-54.76	-44.1	-64.75
Shares Outstanding (Basic)	44	41	6	5	5
Shares Outstanding (Diluted)	44	41	6	5	5
Shares Change (YoY)	250.28%	536.74%	20.01%	6.13%	-
EPS (Basic)	-1.51	-1.81	-8.60	-8.31	-12.96
EPS (Diluted)	-1.51	-1.81	-8.60	-8.31	-12.96
Free Cash Flow	-61.12	-56.22	-51.67	-32.85	-60.98
Free Cash Flow Per Share	-1.39	-1.39	-8.12	-6.19	-12.20
Gross Margin	57.15%	55.40%	55.11%	52.59%	100.00%
Operating Margin	-70.13%	-71.50%	-69.48%	-298.88%	-36784.40%
Profit Margin	-60.27%	-73.02%	-84.08%	-367.64%	-36173.70%
FCF Margin	-55.45%	-56.08%	-79.34%	-273.84%	-34067.00%
EBITDA	-75.46	-70.11	-44.1	-34.62	-64.5
EBITDA Margin	-68.45%	-69.93%	-67.72%	-288.65%	-36033.00%
EBIT	-77.31	-71.68	-45.25	-35.85	-65.84
EBIT Margin	-70.13%	-71.50%	-69.48%	-298.88%	-36784.40%

SEC Filings: 10-K · 10-Q